Primary endpoints of phase III trials for older patients with cancer

被引：1
|
作者：
Mizutani, T. [1 ]
机构：
[1] Kyorin Univ, Fac Med, Dept Med Oncol, Mitaka, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1674
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1702P
引用
收藏
页码：S1187 / S1187
页数：1
相关论文
共 50 条
  • [1] Endpoints for Phase III Trials
    van den Bent, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S40 - S40
  • [2] Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
    Mizutani, T.
    Uemura, K.
    Sato, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S1081 - S1081
  • [3] Comparison of primary endpoints between publications, registries, and protocols of phase III cancer clinical trials
    Liang, Fei
    Guo, Xinmei
    Zhang, Sheng
    Xue, Hongxi
    Chen, Qiang
    Hu, Xichun
    ONCOTARGET, 2017, 8 (57) : 97648 - 97656
  • [4] Primary endpoints for randomised trials of cancer therapy
    Cuzick, Jack
    LANCET, 2008, 371 (9631): : 2156 - 2158
  • [5] Phase III XELOX trial in metastatic colorectal cancer meets primary endpoints
    不详
    ONCOLOGY-NEW YORK, 2006, 20 (14): : 1871 - 1872
  • [6] Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review
    Zichi, Clizia
    Paratore, Chiara
    Gargiulo, Piera
    Mariniello, Annapaola
    Reale, Maria Lucia
    Audisio, Marco
    Bungaro, Maristella
    Caglio, Andrea
    Gamba, Teresa
    Perrone, Francesco
    Di Maio, Massimo
    EUROPEAN JOURNAL OF CANCER, 2021, 149 : 49 - 60
  • [7] Primary Endpoints in Current Phase II/III Trials for Alzheimer Disease A Systematic Survey of Trials Registered at ClinicalTrials.gov
    Takeshima, Nozomi
    Ishiwata, Keita
    Sozu, Takashi
    Furukawa, Toshi A.
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2020, 34 (01): : 97 - 100
  • [8] PRIMARY AND SECONDARY ENDPOINTS USED IN RECENT (2022) ALZHEIMER'S DISEASE (AD) PHASE III CLINICAL TRIALS
    Arjunji, R.
    Massey, J.
    Maru, B.
    Crosland, E.
    Gregory, S.
    Kern, R.
    VALUE IN HEALTH, 2023, 26 (06) : S53 - S54
  • [9] Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials
    You, B.
    Gan, H. K.
    Pond, G. R.
    Chen, E. X.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Time to change the paradigm for primary endpoints in cancer screening trials?
    Malagon, Talia
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (08): : 1187 - 1189
12345